- Zacks Small Cap Research•3 months agoIMNP: Phase 2 Clinical Trials of Bertilimumab Ongoing; Subsidiary to Develop Immunooncology Products.…
By David Bautz, PhD NASDAQ:IMNP Financial Update On March 30, 2016, Immune Pharmaceuticals, Inc. (IMNP) announced financial results for the fourth quarter and full year 2015 and provided a business update. ...
- Zacks Small Cap Research•8 months ago
On November 11, 2015, Immune Pharmaceuticals, Inc. (IMNP) announced financial results for the third quarter of 2015 and provided a business update. This acceptance will enable the company to expand recruitment for the ongoing Phase 2 clinical trial to three planned clinical trial sites in the U.S., including Mount Sinai School of Medicine in New York City.
Immune Pharmaceuticals, Inc.NasdaqCM
After hours: 0.390.01 (1.43%) as of 6:42 PM EDT
|Bid||0.36 x 5000|
|Ask||0.39 x 900|
|52wk Range||0.20 - 1.88|
|Day's Range||0.36 - 0.40|
|Avg Vol (3m)||1,426,034|
As of 4:00 PM EDT. Market closed.